NCT06128070View on ClinicalTrials.gov

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 16, 2024

Primary Completion Date

November 22, 2030

Study Completion Date

November 22, 2030

Conditions
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Chest Computed Tomography

Undergo chest CT

PROCEDURE

Echocardiography

Undergo ECHO

PROCEDURE

Hematopoietic Cell Transplantation

Undergo HCT

DRUG

Methotrexate

Given IV

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

DRUG

Ruxolitinib Phosphate

Given PO

DRUG

Tacrolimus

Given IV

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER